Literature DB >> 36040595

Endocardial Gene Delivery Using NOGA Catheter System.

Satu Siimes1, Niko Järveläinen1, Henna Korpela1, Seppo Ylä-Herttuala2,3.   

Abstract

NOGA/MyoStar system uses low magnetic fields and endomyocardial electrical parameters, allowing precise endomyocardial injections of therapeutic agents to ischemic yet viable myocardium which is most likely to respond to the treatment. Preclinical and clinical studies have shown that NOGA/MyoStar guided intramyocardial injections are safe, feasible and a minimally invasive way to deliver gene therapy to the heart. Here we describe how to perform electroanatomical mapping and injections to hibernating myocardium in the preclinical studies.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Endocardial gene delivery; Gene delivery; Gene therapy; MyoStar; NOGA

Mesh：

Year:  2022        PMID： 36040595     DOI： 10.1007/978-1-0716-2707-5_14

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  13 in total

1.  Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart.

Authors:  Juha Rutanen; Tuomas T Rissanen; Johanna E Markkanen; Marcin Gruchala; Päivi Silvennoinen; Antti Kivelä; Antti Hedman; Marja Hedman; Tommi Heikura; Maija-Riitta Ordén; Steven A Stacker; Marc G Achen; Juha Hartikainen; Seppo Ylä-Herttuala
Journal:  Circulation       Date:  2004-02-16       Impact factor: 29.690

Review 2.  Endoventricular electromechanical mapping-the diagnostic and therapeutic utility of the NOGA XP Cardiac Navigation System.

Authors:  Peter J Psaltis; Stephen G Worthley
Journal:  J Cardiovasc Transl Res       Date:  2008-12-10       Impact factor: 4.132

3.  A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease.

Authors:  Shmuel Fuchs; Nabil Dib; Barry M Cohen; Petros Okubagzi; Edward B Diethrich; Ann Campbell; Jennifer Macko; Paul D Kessler; Henrik S Rasmussen; Stephen E Epstein; Ran Kornowski
Journal:  Catheter Cardiovasc Interv       Date:  2006-09       Impact factor: 2.692

4.  Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease.

Authors:  Rasmus Sejersten Ripa; Yongzhong Wang; Erik Jørgensen; Hans Erik Johnsen; Birger Hesse; Jens Kastrup
Journal:  Eur Heart J       Date:  2006-07-06       Impact factor: 29.983

5.  Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.

Authors:  Jens Kastrup; Erik Jørgensen; Andreas Rück; Kristina Tägil; Dietmar Glogar; Witold Ruzyllo; Hans Erik Bøtker; Dariusz Dudek; Viktor Drvota; Birger Hesse; Leif Thuesen; Pontus Blomberg; Mariann Gyöngyösi; Christer Sylvén
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

6.  Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia.

Authors:  P R Vale; D W Losordo; C E Milliken; M C McDonald; L M Gravelin; C M Curry; D D Esakof; M Maysky; J F Symes; J M Isner
Journal:  Circulation       Date:  2001-05-01       Impact factor: 29.690

7.  Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD).

Authors:  Krzysztof Kukuła; Lidia Chojnowska; Maciej Dąbrowski; Adam Witkowski; Zbigniew Chmielak; Mirosław Skwarek; Jacek Kądziela; Anna Teresińska; Maciej Małecki; Przemysław Janik; Zbigniew Lewandowski; Mariusz Kłopotowski; Jacek Wnuk; Witold Rużyłło
Journal:  Am Heart J       Date:  2011-01-31       Impact factor: 4.749

8.  A characterization and targeting of the infarct border zone in a swine model of myocardial infarction.

Authors:  Jason M Duran; Sharven Taghavi; Remus M Berretta; Catherine A Makarewich; Thomas Sharp Iii; Tim Starosta; Foram Udeshi; Jon C George; Hajime Kubo; Steven R Houser
Journal:  Clin Transl Sci       Date:  2012-06-26       Impact factor: 4.689

9.  Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms.

Authors:  Johanna E Lähteenvuo; Markku T Lähteenvuo; Antti Kivelä; Carolina Rosenlew; Annelie Falkevall; Joakim Klar; Tommi Heikura; Tuomas T Rissanen; Elisa Vähäkangas; Petra Korpisalo; Berndt Enholm; Peter Carmeliet; Kari Alitalo; Ulf Eriksson; Seppo Ylä-Herttuala
Journal:  Circulation       Date:  2009-02-02       Impact factor: 29.690

10.  VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial.

Authors:  Duncan J Stewart; Michael J B Kutryk; David Fitchett; Michael Freeman; Nancy Camack; Yinghua Su; Anthony Della Siega; Luc Bilodeau; Jeffrey R Burton; Guy Proulx; Sam Radhakrishnan
Journal:  Mol Ther       Date:  2009-04-07       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.